790 results on '"Rauh, Daniel"'
Search Results
2. Persister state-directed transitioning and vulnerability in melanoma
3. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
4. Chemische Biologie
5. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC
6. Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
7. Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
8. 11th German Conference on Chemoinformatics (GCC 2015) : Fulda, Germany. 8-10 November 2015.
9. Order of Decay of Mobile Charge Carriers in P3HT:PCBM Solar Cells
10. Cellular model system to dissect the isoform-selectivity of Akt inhibitors
11. Relation of open circuit voltage to charge carrier density in organic bulk heterojunction solar cells
12. Detailed study of N,N'-(diisopropylphenyl)- terrylene-3,4:11,12-bis(dicarboximide) as electron acceptor for solar cells application
13. Energetics of Excited States in the Conjugated Polymer Poly(3-hexylthiophene)
14. Correction: A high-throughput effector screen identifies a novel small molecule scaffold for inhibition of ten-eleven translocation dioxygenase 2
15. Effect of doping-- and field--induced charge carrier density on the electron transport in nanocrystalline ZnO
16. Reply to Y. Xia et al.
17. 2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach
18. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
19. An Unbiased Cell Morphology–Based Screen for New, Biologically Active Small Molecules
20. Fragtory: Pharmacophore-Focused Design, Synthesis, and Evaluation of an sp3-Enriched Fragment Library
21. A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives
22. Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines
23. Abstract 3887: ATP-binding pocket substitutions as secondary or tertiary in-cis mutations are major on-target ripretinib resistance mechanisms in gastrointestinal stromal tumor
24. Supplementary Data from Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain
25. Data from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
26. Data from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
27. Interview with Dr. Meyerson from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
28. Supplementary Methods and Legends from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
29. Supplementary Figure Legends 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
30. Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
31. Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
32. Data from Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain
33. Supplementary Figures S1-S14 from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer
34. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
35. Data from ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
36. Supplementary Figures 1-9 from ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
37. Supplementary Figure Legends 1-9 from ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
38. Supplementary Table 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
39. Supplementary Figure 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
40. Supplementary Methods, Figure Legends 1-3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
41. Supplementary Figure 3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
42. Supplementary Table 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
43. Supplementary Figure 4 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
44. Supplementary Figure 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
45. Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
46. Insights into the Conformational Plasticity of the Protein Kinase Akt1 by Multi‐Lateral Dipolar Spectroscopy
47. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
48. Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR
49. Additional file 1 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
50. Additional file 2 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.